Heterozygous mutations in CTLA-4 have been associated with a spectrum of clinical manifestations, including autoimmune disorders targeting specific organs, hypogammaglobulinemia, recurrent infections, and susceptibility to certain cancers [30]. Here, CTLA4 is linked to autoimmune disease.